Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Viread Approved for Hepatitis B


Already sanctioned to treat HIV

TUESDAY, Aug. 12 (HealthDay News) -- Viread (tenofovir disoproxil fumarate) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis B infection in adults.

The Gilead Sciences drug has been approved since 2001 to treat HIV/AIDS.

A serious liver disease, chronic hepatitis B affects about 400 million people globally and some 2 million in the United States, the manufacturer said in a news release. Asian Americans account for nearly half of all cases of the infection, which is a leading cause of liver cancer.

A once-daily tablet, Viread blocks an enzyme called HBV DNA polymerase, which is needed by the hepatitis B virus to replicate in liver cells.

More information

The FDA has more about this drug's approval history.
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision